July 4th, 2024. Ghent, Belgium.
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
Anacura is an independent analytical centre of excellence in both healthcare and drug development, offering personalised and evidence-based laboratory solutions. The group supports health care providers and patients through medical analyses at Labo Nuytinck and assists pharmaceutical and biotech companies with end-to-end drug development analytics at AnaBioTec.
Anacura CEO Griet Nuytinck: “The acquisition of OHMX.bio is a next step in anacura’s aim to remain a frontrunner in innovative healthcare services, complementing ongoing initiatives within our existing business units. With the acquisition, we bring in a company with deep scientific expertise that shares our key values, enabling us to bring an even stronger service offering to the biotech community in Belgium and beyond.”
Established in 2019 as a Ghent University spin-off, OHMX.bio operates as a premier study design company, specializing in cutting-edge -omics technologies for discovery and (pre)clinical studies. The company leverages multi-omic technologies, such as next-generation sequencing, in combination with advanced bio-informatics to speed up the discovery process and quality control of advanced therapy medicinal products like CAR-T.
OHMX.bio CEO/CSO Gerben Menschaert: “Our activities complement the current service offering within the anacura group, and importantly, we share the same values, mission and drive for quality, scientific excellence, and a tailored personal approach.”
Menschaert is one of the co-founders of OHMX.bio and affiliated as a professor to the Lab of Bioinformatics and Computational Genomics at Ghent University.
“OHMX.bio joining the anacura family is a future proof move for both parties,” he says, “It will allow OHMX.bio to expand its portfolio and tap into new markets and it strengthens anacura’s offering of innovative technologies. Collectively, we solidify anacura’s position as a one-stop shop for clients and market leader in the Ghent Biotech ecosystem.”